EUCTR2006-004073-10-DE
Active, not recruiting
Not Applicable
Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD - Atomoxetine and adult ADHD
niversity of Giessen0 sitesAugust 16, 2006
ConditionsAdult Attention Deficit Hyperactivity DisorderMedDRA version: 8.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorder
DrugsStrattera
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Sponsor
- niversity of Giessen
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Actual diagnosis of ADHD according to DSM IV
- •Age 18 to 50
- •Both sexes
- •Declaration of informed consent for all clinical measures
- •Normal IQ (Estimated by a short IQ test during the screening)
- •Normal ECG findings
- •Sufficient knowledge of the German language to follow instructions and training procedure
- •In\- and out\-patients
- •Consent to a highly effective birth control method (failure rate less than 1%) for female patients in childbearing years
- •Are the trial subjects under 18? no
Exclusion Criteria
- •Other psychiatric disorder according to DSM IV
- •Any neurological disorder
- •Tachykardia, hyperpiesia or very low blood pressure
- •Liver malfunctions
- •Contraindication for the usage of Atomoxetine as listed in the companies safety information
- •Intake of antibiotics, azol\-antimycotics, antihistamines or antiarrhythmics
- •History of allergic reaction to Atomoxetine
- •Female patients who are pregnant or nursing
- •Other medication that affects the central nervous system
- •Paticipation in other clinical trials
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
Not yet recruiting
Phase 3
Atomoxetine for cognitive impairment in Behcet's diseaseIRCT20211206053288N1Tehran University of Medical Sciences40
Recruiting
Phase 3
The Effect of Atomoxetine on Cognitive Symptoms in Schizophrenia PatientsIRCT20211219053452N1Arak University of Medical Sciences40
Recruiting
Phase 2
Effectiveness of Atomoxetine treatment for methamphetamine use disorderOther stimulants dependence syndrome.Dependence syndrome: A cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despiteF15.24IRCT2017070234844N1Tehran University of Medical Sciences (TUMS), Vice-chancellor for Research90
Active, not recruiting
Phase 1
Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.EUCTR2019-004455-36-FRCHU DE POITIERS45